Ann: Imagion Biosystems December 2021 Investor Newsletter, page-11

Bob states he is pleased with the recent progress of the clinical trials . That for me is a major highlight point. Its probably about as much as he can say at this time given disclosure rules in view of the fact they will not release trial results until a sufficient cohort of patients have been tested. Also the new US facility is intended for ramping up nanoparticle production and having a Director of Operations now on-board suggests things are hotting up. All seems positive to me. And the newsletters are most welcome